Dr O'Shaughnessy on Real-World Data for Tucatinib-Based Therapy in HER2+ Breast Cancer

Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.

Related Keywords

San Antonio ,Texas ,United States ,Joycea Oshaughnessy , ,Baylor Sammons Cancer Center ,Flatiron Health Metastatic Breast Cancer ,Us Oncology Research Network ,Breast Cancer Research ,Breast Cancer Prevention Research ,Us Oncology Network ,Scientific Advisory Board ,Research Network ,Antonio Breast Cancer Symposium ,Baylor Scott Amp White Charlesa Sammons Cancer Center Gt Centers ,Ther2 ,Onclive Tv ,Breast Cancer ,